Ashish Kamat, MD
Urology · Houston, TXNPI 1114012895
Payments from drug & device makers
Across 301 payments — averaging $3179.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$356K
- Merck$142K
- Pfizer$119K
- Janssen Research & Development, LLC$108K
- Ferring Pharmaceuticals Inc.$52K
- AstraZeneca$34K
- plus $146K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 30 | $356,292 |
| Merck | 74 | $141,673 |
| Pfizer | 26 | $119,056 |
| Janssen Research & Development, LLC | 30 | $108,281 |
| Ferring Pharmaceuticals Inc. | 32 | $51,720 |
| AstraZeneca | 13 | $33,749 |
| KARL Storz Endoscopy-america | 7 | $27,185 |
| Urogen Pharma, Inc. | 7 | $19,387 |
| Janssen Global Services, LLC | 21 | $17,560 |
| E.r. Squibb & Sons, L.L.C. | 12 | $14,021 |
| Janssen Scientific Affairs, LLC | 4 | $10,715 |
| Astellas Pharma US Inc | 4 | $9,851 |
| Photocure Inc | 8 | $8,819 |
| Abbott | 6 | $7,094 |
| Eisai Inc. | 6 | $6,580 |
| Astellas Pharma Global Development | 4 | $6,295 |
| Ferring Pharmaceuticals AS | 1 | $6,293 |
| Incyte Corporation | 1 | $2,768 |
| Nonagen Bioscience Corp | 2 | $2,625 |
| F. Hoffmann-la Roche AG | 1 | $1,950 |
| Astrazeneca UK Limited | 1 | $1,663 |
| Verity Pharmaceuticals Inc. | 1 | $1,600 |
| Genentech, Inc. | 2 | $1,094 |
| Johnson & Johnson(2 entities) | 2 | $561 |
| Boston Scientific | 1 | $120 |
| Convatec Inc. | 1 | $44 |
| Exelixis Inc. | 2 | $40 |
| 180 Medical, Inc. | 1 | $29 |
| Astellas Pharma Inc | 1 | $14 |
How this compares
$957,079 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Houston
- Zvi SchiffmanHouston$17.8M
- Jose KaramHouston$5.7M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Brian ChapinHouston$1.1M
- Arun RaiHouston$1M
- Donald GriffithHouston$732K
- Robert CornellHouston$695K
- John DavisHouston$669K
- Neema NavaiHouston$607K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.